6 Results for "

mouse model of thigh infection

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "mouse model of thigh infection" in MCE Product Catalog:

Cat. No.: HY-125356
CAS No.: 2209871-83-8
Target:  

Beta-lactamase

Research Areas:  

Infection

ETX0282 is an orally active prodrug, with its active form being ETX1317. ETX0282 and ETX1317 are β-lactamase inhibitors of the dioxolane-dibenzo-p-heptane (DBO) type. ETX0282 exhibits high stability during intestinal absorption and can be efficiently converted into ETX1317 in the liver. ETX0282 alone has no bactericidal activity, but in a mouse model of neutropenic thigh infection, it can significantly reduce bacterial load when used in combination with Cefpodoxime Proxetil (HY-N7101). ETX0282 can be used for the study of infections caused by drug-resistant Gram-negative bacteria .
loading...
    loading...
Cat. No.: HY-156122
CAS No.: 3032441-09-8
Research Areas:  

Infection

DHFR-IN-8 (compound 6r) is a dihydrofolate reductase (DHFR) inhibitor that affects purine and thymidylate biosynthesis in cell proliferation and growth. DHFR-IN-8 inhibits methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 (IC50=15.6 ng/mL) in mouse models of systemic infection and thigh infection .
loading...
    loading...
Cat. No.: HY-117951
CAS No.: 1639972-90-9
Target:  

Beta-lactamase

Research Areas:  

Infection

ANT431 is a metallo-β-lactamase inhibitor that also restores the effectiveness of Meropenem (HY-13678) in a mouse thigh Escherichia coli infection model .
loading...
    loading...
Cat. No.: HY-156123
CAS No.: 3032441-13-4
Research Areas:  

Infection Cancer

DHFR-IN-9 (compound 8A) is a dihydrofolate reductase (DHFR) inhibitor that affects purine and thymidylate biosynthesis in cell proliferation and growth. DHFR-IN-9 inhibits methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 (IC50=0.25 μg/mL) and has anti-infective effects in mouse models of systemic infection and thigh infection caused by it (dose: 2.5 mg /kg, 5 mg/kg; ip). DHFR-IN-9 has stronger anticancer activity than paclitaxel (Y-B0015) in a mouse model of breast cancer (dose: 2.5 mg/kg; ip; once every 3 days) .
loading...
    loading...
Cat. No.: HY-182936
Research Areas:  

Infection

Antibacterial agent 338 (Compound 65) is an antibacterial agent and GyrB inhibitor, with an IC50 of 12.60 nM against GyrB from E. coli. Antibacterial agent 338 binds to the ATP-binding domain of E. coli GyrB, thereby inhibiting the ATPase activity of GyrB. Antibacterial agent 338 exhibits broad-spectrum antibacterial activity against multidrug-resistant Gram-negative bacteria. Antibacterial agent 338 reduces bacterial load in a neutropenic mouse thigh infection model. Antibacterial agent 338 can be used for the research of Acinetobacter baumannii infection .
loading...
    loading...
Cat. No.: HY-W923278
CAS No.: 73547-70-3
Synonyms: GR20263 dihydrochloride
Target:  

Antibiotic Bacterial

Research Areas:  

Infection

Ceftazidime (GR20263) dihydrochloride is a cephalosporin β-lactam antibiotic. Ceftazidime dihydrochloride exhibits activity against susceptible Enterobacteriaceae, multidrug-resistant Gram-negative bacteria, Pseudomonas aeruginosa, and bacteria producing Ambler class A, C, and some class D β-lactamases, but shows no activity against microorganisms producing metallo-β-lactamases. Ceftazidime dihydrochloride reduces bacterial loads in mouse models of splenic, hepatic, and thigh infections, but has low efficacy against ESBL- and KPC-producing Enterobacteriaceae. Ceftazidime dihydrochloride can be used in research related to complicated urinary tract infections, complicated intra-abdominal infections, hospital-acquired pneumonia, carbapenemase-producing Klebsiella pneumoniae infections, carbapenem-resistant Enterobacterales infections, and severe Gram-negative bacterial infections .
loading...
    loading...